Cite

HARVARD Citation

    Lew, E. et al. (n.d.). Immuno-oncologic efficacy of RXDX-106, a selective, TAM family small molecule kinase inhibitor. European journal of cancer. pp. S31-. [Online]. 
  
Back to record